AVITA Medical, Inc. (AVH.AX)
| Previous close | 1.5750 |
| Open | 1.5500 |
| Bid | 1.4700 x 734600 |
| Ask | 1.4800 x 258500 |
| Day's range | 1.4600 - 1.5600 |
| 52-week range | 1.2800 - 5.7000 |
| Volume | |
| Avg. volume | 326,887 |
| Market cap | 184.671M |
| Beta (5Y monthly) | 0.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3010 |
| Earnings date | 29 Apr 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.15 |
- Zacks
Does Avita Medical Inc. (RCEL) Have the Potential to Rally 210% as Wall Street Analysts Expect?
The mean of analysts' price targets for Avita Medical Inc. (RCEL) points to a 209.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- GlobeNewswire
AVITA Medical Reports First Quarter 2022 Financial Results
VALENCIA, Calif. and MELBOURNE, Australia, May 12, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (the “Company”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its first quarter ended March 31, 2022. Financial Highlights and Recent Updates: Reported commercial revenue, which excludes BARDA revenue, of $7.4 mil
- GlobeNewswire
RECELL® System to be Highlighted at Upcoming Music City SCALE Multidisciplinary Dermatology Meeting
VALENCIA, Calif. and MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that a discussion on the RECELL System will be held during the Symposium for Cosmetic Advances & Laser Education (SCALE) multidisciplinary dermatology meeting taking place May 11
